3/18
09:18 am
dwtx
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/18
08:30 am
dwtx
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2/20
08:03 am
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
2/2
05:42 pm
dwtx
DWTX: Financing Secures Funding Through Phase 2b Data Readout [Yahoo! Finance]
Medium
Report
DWTX: Financing Secures Funding Through Phase 2b Data Readout [Yahoo! Finance]
2/2
09:17 am
dwtx
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 [Yahoo! Finance]
Medium
Report
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 [Yahoo! Finance]
2/2
08:30 am
dwtx
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Low
Report
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
1/30
08:03 am
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
1/12
08:30 am
dwtx
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Medium
Report
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development